Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5374545 | 0.83 | MAOB (0.34) | MAOAMAOB | |
| SCHEMBL6360450 | 0.68 | MAOA (0.36) | MAOAMAOBKDM1ASLC6A4SLC6A3 | |
| SCHEMBL12696323 | 0.67 | MAOB (0.42) | MAOAMAOBKDM1ASLC6A4SLC6A3 | |
| SCHEMBL6361145 | 0.66 | MAOA (0.34) | MAOAMAOBKDM1ASLC6A4SLC6A3 | |
| SCHEMBL4078451 | 0.63 | — | — | |
| SCHEMBL668905 | 0.60 | SLC6A4 (0.47) | MAOAMAOBKDM1ASLC6A4SLC6A3 | |
| SCHEMBL4803476 | 0.58 | — | — | |
| SCHEMBL1492744 | 0.57 | SLC6A4 (0.48) | MAOAMAOBKDM1ASLC6A4SLC6A3 | |
| SCHEMBL8478708 | 0.57 | SLC6A4 (0.53) | SLC6A4SLC6A3 | |
| SCHEMBL4125543 | 0.55 | SLC6A4 (0.57) | SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208507-B2 | Lysophosphatidic acid acyltransferase beta inhibitors; antiproliferative agents, treating tumors; [2-Chloro-6-(5-chloro-2-methoxy-phenyl)-pyridin-4-yl]-p-tolyl-amine for example | CELL THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20070178134-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| US-7208507-B2 | Lysophosphatidic acid acyltransferase beta inhibitors; antiproliferative agents, treating tumors; [2-Chloro-6-(5-chloro-2-methoxy-phenyl)-pyridin-4-yl]-p-tolyl-amine for example | CELL THERAPEUTICS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050182102-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| US-6875781-B2 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20040198728-A1 | Pyridines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198728-A1 | Pyridines and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MAOA 535/4885MAOB 833/4885KDM1A 880/4885 |
| US-20070178134-A1 | Pyridines and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MAOA 684/4885MAOB 753/4885KDM1A 1010/4885 |
| US-20050182102-A1 | Pyridines and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MAOA 684/4885MAOB 753/4885KDM1A 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.